Clinical Trial Update: QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of the Ad5 [E1-, E2b-]-HER2/Neu vaccine (ETBX-021) in unresectable locally advanced or metastatic HER2-expressing breast cancer was terminated; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ETBX-021 Ad5 [E1-, E2b-]-HER2/Neu vaccine (Ad5 [E1-, E2b-]-HER2/Neu vaccine)

Snippet

Sponsor: NantBioScience, Inc. | Conditions: Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-01-13